Results 51 to 60 of about 2,540 (169)

Targeting inflammation in cardiometabolic disease: Icosapent ethyl modulates monocyte‐derived macrophages isolated from patients with cardiovascular disease with or without type 2 diabetes

Diabetic Medicine, Volume 43, Issue 4, April 2026.
Abstract Aims Despite intensive lipid‐lowering therapy, individuals with atherosclerotic cardiovascular disease (ASCVD) exhibit residual inflammatory risk, which drives recurrent cardiovascular events. This risk is amplified in type 2 diabetes mellitus (T2DM), where a pro‐inflammatory milieu accelerates atherogenesis. Monocyte‐derived macrophages (MDMs)
J. K. Ward, M. U. Shah, K. Lee, P. E. Squires, C. E. Hills   +4 more
wiley   +1 more source

Advancing the Landscape of RNAi Nanotherapeutics for Ischemic Heart Disease

Advanced Materials, Volume 38, Issue 17, 20 March 2026.
RNA interference (RNAi) nanomedicine revolutionizes treatment regimens for ischemic heart diseases by enabling tailored, sequence‐anchored gene regulation. This review highlights the recent advances in nanotechnology‐driven RNAi therapeutics for myocardial ischemia and discusses the key design principles that govern efficient delivery, providing ...
Han Gao, Da Pan, Hélder A. Santos
wiley   +1 more source

Harnessing RNA Interference for Cholesterol Lowering: The Bench‐to‐Bedside Story of Inclisiran

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Lowering low‐density lipoprotein cholesterol (LDL‐C) is a cornerstone of reducing risk for atherosclerotic cardiovascular disease. Despite the approval of nonstatin therapies for LDL‐C lowering over the past 2 decades, these medications are underused ...
Michael J. Wilkinson, Archna Bajaj, Margaret E. Brousseau, Pam R. Taub   +3 more
doaj   +1 more source

RNA‐Based Therapies for Inherited Metabolic Disorders

Journal of Inherited Metabolic Disease, Volume 49, Issue 2, March 2026.
ABSTRACT Inherited metabolic disorders (IMDs) are a diverse and complex group of genetic conditions resulting from deficiencies in enzymes, transporters, or cofactors. These deficiencies lead to metabolic dysfunction and severe clinical consequences. Despite significant progress in understanding their molecular basis, treatment options remain limited ...
Reddy Sreekanth Vootukuri, Sonam Gurung, Roopkatha Ghosh, Philippa B. Mills, Julien Baruteau, Haiyan Zhou   +5 more
wiley   +1 more source

Progress in RNA‐Targeted Therapeutics for Human Diseases

MedComm, Volume 7, Issue 2, February 2026.
RNA‐targeted therapies are revolutionizing molecular medicine by transitioning from a “protein‐centric” focus to an “RNA‐regulatory network” approach. Leveraging RNA's diverse roles in gene regulation, signaling, and epigenetic modifications, advanced platforms such as ASOs, siRNA, miRNA, mRNA, aptamers, shRNA, and CRISPR/Cas systems are enabling ...
Wangzheqi Zhang, Aimin Jiang, Bin‐Kui Jia, Yuming Jin, Yinghu Chen, Zhaoyu Li, Yan Liao, Haoling Zhang, Zhiheng Lin, Xiao Fang, Linhui Wang   +10 more
wiley   +1 more source

National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian Clinical Guideline for Diagnosing and Managing Acute Coronary Syndromes 2025

Medical Journal of Australia, Volume 224, Issue 2, February 2026.
ABSTRACT Introduction The Australian clinical guideline for diagnosing and managing acute coronary syndromes 2025 establishes a new clinical standard for the diagnosis and management of acute coronary syndromes (ACS) in Australia. The new guideline replaces the 2016 guideline, representing the first major update in nearly a decade.
David B. Brieger, Louise A. Cullen, Tom G. Briffa, Sarah Zaman, Ian A. Scott, Cynthia Papendick, Elaine Ho, Victoria Leitch, Dannii Dougherty, Garry Jennings   +9 more
wiley   +1 more source

Safety of Inclisiran: A Disproportionality Analysis from the EudraVigilance Database

Pharmaceuticals
Introduction: The discovery of serine protease proprotein convertase subtilisin-kexin type 9 (PCSK9) has revolutionized pharmacological lipid-lowering treatments.
Giuseppe Cicala, Michelangelo Rottura, Viviana Maria Gianguzzo, Federica Cristiano, Selene Francesca Anna Drago, Giovanni Pallio, Natasha Irrera, Egidio Imbalzano, Edoardo Spina, Vincenzo Arcoraci   +9 more
doaj   +1 more source

Rationale and Design of the PASSIVATE‐CAP Trial: The Preventive Intervention Value of Drug‐Coated Balloons in Vulnerable Coronary Atherosclerotic Plaques

Clinical Cardiology, Volume 49, Issue 1, January 2026.
PASSIVATE‐CAP Research Overview and Flowchart. ABSTRACT Background Patients with acute coronary syndrome (ACS) face a significantly increased risk of cardiovascular events due to vulnerable plaques. However, no clear evidence supports performing preventive percutaneous coronary intervention (PCI) for non‐flow‐limiting vulnerable plaques.
Zhongxiu Chen, Junyan Zhang, Minggang Zhou, Shichu Liang, Yong Chen, Chen Li, Hua Wang, Jiafu Wei, Baotao Huang, Mian Wang, Yong He, for the PASSIVATE‐CAP trial investigator   +11 more
wiley   +1 more source

Optimization of 4‐Amino‐2‐Pyridone Inhibitors of Proprotein Convertase Subtilisin/Kexin Type 9: Integrating Structure–Activity and Structure–Metabolism Relationships

ChemMedChem, Volume 21, Issue 1, January 2026.
Green chemistry‐based late‐stage functionalization (LSF) of the anti‐proprotein convertase subtilisin/kexin type 9 (PCSK9) early lead compound 5c led to optimized analogs with improved metabolic stability/PCSK9 IC50 ratio. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key drug target for the treatment of different hypercholesterolemia ...
Lisa Giannessi, Maria Giovanna Lupo, Martina Ugolotti, Bianca Papotti, Beatrice Mattina, Maria Grazia Martina, Anna Demurtas, Cristina Padula, Sara Nicoli, Marco Crescenzio, Nicola Ferri, Francesca Zimetti, Marco Radi   +12 more
wiley   +1 more source

Course of Pregnancy in a Woman With Familial Chylomicronemia Syndrome Treated With Plozasiran, a Small Interfering RNA Against ApoC3

JIMD Reports, Volume 67, Issue 1, January 2026.
ABSTRACT Persistent chylomicronemia is associated with severe hypertriglyceridemia (sHTG) and plasma triglycerides (TG) levels sustainably > 10 mmol/L (880 mg/dL) despite lipid lowering therapies. The main risk of persistent chylomicronemia is acute pancreatitis (AP). During the second and third trimester of pregnancy, TG levels significantly increase,
Miriam Larouche, Diane Brisson, Nathalie Roy, Claudy Grenon, Paul Poirier, Ma'an Muhsin, Daniel Gaudet   +6 more
wiley   +1 more source